



## IBA S.A. successfully completes sale of IBA Molecular

**Louvain-la-Neuve, Belgium – 23 March 2016** - IBA (Ion Beam Applications S.A.) the world's leading provider of proton therapy solutions for the treatment of cancer, today announces that the sale of IBA Molecular ("IBAM") in which IBA had a 40% stake, to funds advised by CapVest Partners LP ("CapVest"), has closed successfully. With this transaction, IBA has fully exited its joint venture with SK Capital Partners and retains no interests in IBA Molecular.

The closing of this transaction is completed by a payment in cash to IBA of circa EUR 62 million.

**Olivier Legrain, Chief Executive Officer of IBA, commented:** "With this transaction we have achieved another key milestone in the streamlining of our business to focus on proton therapy, enabling us to concentrate on delivering the highest standard of modern cancer treatment to patients."

\*\*\*END\*\*\*

### About IBA

IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The Company is the worldwide technology leader in the field of proton therapy, the most advanced form of radiation therapy available today. IBA's proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full scale proton therapy centers as well as compact, single room systems. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry.

Headquartered in Belgium and employing about 1,200 people worldwide, IBA has installed systems across the world, from Europe and the US and to the emerging markets. IBA is listed on the pan-European stock exchange EURONEXT. (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB) and more information can be found at: [www.iba-worldwide.com](http://www.iba-worldwide.com)

### About CapVest

CapVest is an established European mid-market private equity firm focused on acquiring market leading companies supplying essential products and services. The firm places an emphasis on driving business growth through active management and has demonstrated consistent success in creating long-term value. For more information, visit [www.capvest.co.uk](http://www.capvest.co.uk)

# Press release |

Regulated information



## For further information please contact:

### **IBA**

Jean-Marc Bothy  
Chief Financial Officer  
+32 10 475 890

[Investorrelations@iba-group.com](mailto:Investorrelations@iba-group.com)

Thomas Ralet  
Vice-President Corporate Communication  
+32 10 475 890

[Communication@iba-group.com](mailto:Communication@iba-group.com)

## For media and investor enquiries:

### **Consilium Strategic Communications**

Amber Fennell, Matthew Neal, Ivar Milligan  
+44 (0) 20 3709 5700

[IBA@consilium-comms.com](mailto:IBA@consilium-comms.com)

### **Rx Communications Group (US)**

Melody Carey  
+ 1 917 322 2571

[mcarey@RxIR.com](mailto:mcarey@RxIR.com)